SBPH Spring Bank Pharmaceuticals Inc.

1.75
-0.09  -5%
Previous Close 1.84
Open 1.81
Price To Book 0.68
Market Cap 28,873,142
Shares 16,476,342
Volume 93,190
Short Ratio
Av. Daily Volume 372,994
Stock charts supplied by TradingView

NewsSee all news

  1. Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program

    HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  2. Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019

    HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  3. Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285

    HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  4. Spring Bank Announces Investor Conference Presentations for the Remainder of 2019

    HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  5. Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update

    HOPKINTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initial data presented October 17, 2019. Further data due 2020.
Inarigivir and Vemlidy
Hepatitis B (HBV)
Phase 2 to be initated pending funding.
SB 9200
Respiratory syncytial virus (RSV)
Phase 1 initiation of dosing announced November 20, 2019 with data due mid-2020.
SB 11285
Solid tumors
Phase 2b dosing and enrolment stopped due to hepatocellular dysfunction in three patients.
Inarigivir - (CATALYST 1 and CATALYST 2)
Hepatitis B (HBV)

Latest News

  1. Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program

    HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  2. Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019

    HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  3. Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285

    HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  4. Spring Bank Announces Investor Conference Presentations for the Remainder of 2019

    HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  5. Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update

    HOPKINTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  6. Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY

    HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  7. Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank's STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting

    HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections,

  8. Spring Bank Announces $20 Million Strategic Debt Financing Agreement with Pontifax Medison Finance

    Significant investment demonstrates confidence in Spring Bank's novel development programs Extends Spring Bank's cash runway beyond the end of 2021 Accelerates HBV antisense and STING antagonist development